Addition of CpG ODN to recombinant Pseudomonas aeruginosa ExoProtein A conjugates of AMA1 and Pfs25 greatly increases the number of responders.

Vaccine
Feng QianGregory E D Mullen

Abstract

Both the blood-stage protein apical membrane antigen 1 (AMA1) and the 25-kDa sexual-stage protein (Pfs25) of Plasmodium falciparum are two leading candidates in malarial vaccine development. We have previously demonstrated that conjugation of these malarial antigens to recombinant Pseudomonas aeruginosa ExoProtein A (rEPA) significantly increased the mean-specific functional antibody responses in mice; however, some mice responded poorly and were unable to demonstrate a functional response. We hypothesized that the immunogenicities of these two malarial antigens could be further enhanced by the inclusion of a CpG oligodeoxynucleotide in the formulation. Mice were immunized with either rEPA-conjugated or unconjugated AMA1 and Pfs25 formulated on Alhydrogel with or without the addition of CPG 7909. Mice received the formulations on days 0 and 28, and mouse sera were collected on day 42. ELISA analyses on these sera showed that the addition of CPG 7909 to AMA1-rEPA and Pfs25-rEPA formulated on Alhydrogel induced significantly higher mean antibody titers than the formulations without CPG 7909, and led to a mixed Th1/Th2 response as demonstrated by the production of mouse IgG1 and IgG2a subclasses. The presence of CPG 7909 in the fo...Continue Reading

References

Jan 1, 1992·Memórias do Instituto Oswaldo Cruz·D C KaslowP J Barr
Apr 9, 2001·Infection and Immunity·A N HodderR F Anders
Oct 19, 2006·Vaccine·Marc P GirardMarie Paule Kieny
Nov 18, 2006·Proceedings of the National Academy of Sciences of the United States of America·Yimin WuLouis H Miller
Dec 28, 2006·Proceedings of the National Academy of Sciences of the United States of America·Joanna Kubler-KielbRachel Schneerson
May 22, 2007·Journal of Immunological Methods·Joan A AebigAaron P Miles

❮ Previous
Next ❯

Citations

May 20, 2009·Infection and Immunity·Vanessa SardáKim C Williamson
Jan 11, 2012·Malaria Journal·Lauren SchwartzVasee S Moorthy
Oct 16, 2015·Vaccine·Yimin WuAnjali Yadava
Jan 27, 2009·Advanced Drug Delivery Reviews·Padma MalyalaManmohan Singh
Dec 9, 2014·Human Vaccines & Immunotherapeutics·R Mark JonesVidadi Yusibov
Jan 20, 2015·Expert Review of Vaccines·Daria NikolaevaSumi Biswas
Jan 23, 2021·Expert Review of Vaccines·Patrick E Duffy
Jul 21, 2021·International Journal of Toxicology·Veena V RaoVladimir Savransky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.